Bovilis BVD
ATC code
Species
Cattle (cows and heifers).
Indications
For active immunisation of cows and heifers from eight months of age onwards to protect the foetus against transplacental infection with bovine viral diarrhoea virus.
Dose to be administered and administration route
Before using the vaccine allow it to reach ambient temperature (15 °C – 25 °C).
Shake well before use. Use sterile syringes and needles.
Intramuscular injection. 2 ml per animal.
All cattle can be vaccinated from an age of eight months onwards.
Foetal protection can be expected if the primary immunisation has been finalised 4 weeks before start of the gestation. Animals which are vaccinated later than 4 weeks before gestation or during the early gestation will not be protected against foetal infection.
Individual vaccination
Basic immunisation
Two vaccinations with an interval of 4 weeks. The second vaccination should be given not later than 4 weeks before the start of the gestation.
Revaccination
One vaccination 4 weeks before start of the next gestation.
Herd vaccination
Basic immunisation
Two vaccinations with an interval of 4 weeks. For use in cattle from eight months of age, all animals should be vaccinated.
Revaccination
One vaccination 6 months after basic vaccination with next re-vaccinations at an interval no greater than 12 months.
For revaccination, the vaccine may be used for reconstitution of Bovilis IBR marker live for use in cattle from 15 months of age (i.e. those that have previously been vaccinated separately with Bovilis BVD and Bovilis IBR marker live) and the following instructions should be used:
| Bovilis IBR marker live | Bovilis BVD | |
| 5 doses | + | 10 ml |
| 10 doses | + | 20 ml |
| 25 doses | + | 50 ml |
| 50 doses | + | 100 ml |
A single dose (2 ml) of Bovilis BVD mixed with Bovilis IBR marker live is given intramuscularly.
Visual appearance after reconstitution of Bovilis IBR marker live in Bovilis BVD:
As specified for Bovilis BVD alone.
Adverse reactions
In very rare cases a slight swelling may be observed for 14 days at the site of injection. Also in very rare cases transient mild pyrexia may occur. In very rare cases, hypersensitivity reactions including anaphylactic shock may occur. In the event of anaphylactic type reactions, appropriate treatment such as with antihistamine, corticosteroid or adrenaline is recommended.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
